Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of suprachoroidal triamcinolone acetonide (ARVN001) for macular edema secondary to noninfectious uveitis
CTR20210106Phase 3Active
- Sponsor
- Arctic Vision
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone acetonide in uveitis (2 arms), sponsored by Arctic Vision. Primary endpoint: Proportion of patients with at least 15-letter improvement in BCVA based on ETDRS visual acuity chart. Started Nov 2021; status: active.
02
Drugs
triamcinolone acetonide
03
Conditions
uveitis
Beyond the preview
Go deeper on CTR20210106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210106.